Download PDF

1. Company Snapshot

1.a. Company Description

UFP Technologies, Inc.designs and custom manufactures components, subassemblies, products, and packaging utilizing specialized foams, films, and plastics primarily for the medical market.Its single-use and single-patient devices and components are used in a range of medical devices, disposable wound care products, infection prevention, minimally invasive surgery, wearables, orthopedic soft goods, and orthopedic implant packaging.


The company also provides engineered products and components to customers in the automotive, aerospace and defense, consumer, electronics, and industrial markets, which are applied in military uniform and gear components, automotive interior trim, athletic padding, environmentally protective packaging, air filtration, abrasive nail files, and protective cases and inserts.It markets and sells its products in the United States principally through a direct sales force, as well as independent manufacturer representatives.The company was founded in 1963 and is headquartered in Newburyport, Massachusetts.

Show Full description

1.b. Last Insights on UFPT

UFP Technologies' recent performance was negatively impacted by softer demand and broad-based pricing pressures, as evident in its Q4 2024 earnings miss. The company's revenue growth was hindered by falling lumber prices, which reduced profitability. Additionally, reduced demand in the market led to a decline in sales, further exacerbating the negative trend. Despite a strong net cash position and relative valuation advantages, the company's financial performance has fallen short of expectations.

1.c. Company Highlights

2. UFP Technologies' Robust Growth Continues with 19.5% Sales Increase

UFP Technologies, Inc. reported a strong fourth quarter 2025 earnings, with sales reaching $602.8 million, representing a significant growth. The company's operating income grew 435% and EPS grew 419% over the past four years, demonstrating a remarkable upward trend. For 2025, EPS grew 15.4% to $2.44, beating estimates of $2.26. The company's gross margin decreased to 28.3% due to labor inefficiencies at its Illinois AJR facility, but adjusted operating margin was 17.1% of sales. The effective tax rate was 17.2% for the full year.

Publication Date: Mar -09

📋 Highlights
  • Robust Financial Growth:: Full-year sales rose 19.5% to $602.8M, with operating income surging 435% and EPS growing 419% over four years.
  • EPS Resilience Amid Challenges:: 2025 EPS increased 15.4% despite $6.3M labor inefficiencies at the Illinois AJR facility.
  • Strategic Expansion:: Launched three new programs in La Romana, Dominican Republic, and secured a sixth building for robotic surgery capacity with co-investment from a key customer.
  • Operational Efficiency:: Generated $92.0M cash from operations, reduced debt by $53.9M, and achieved an adjusted operating margin of 17.1% despite gross margin decline to 28.3%.
  • Market Position Strengthening:: Extended the largest customer contract, boosting volumes and adding an additional program, while expanding into high-growth areas like infection prevention and diagnostics.

Strategic Initiatives and Contract Extensions

The company made significant progress on strategic initiatives, including contract extensions, program launches, and facility expansions. It recently negotiated a lease for a third building in Santiago, Dominican Republic, and launched its second major program. The company also launched three significant new programs in La Romana, Dominican Republic, and expanded its contract with its largest customer, materially increasing volumes on existing programs and adding an additional program. As R. Jeffrey Bailly stated, the company is well-positioned for future growth.

Cash Flow and Cash Management

The company generated $92 million in cash from operations, and after paying down $53.9 million in debt, it demonstrated a strong ability to manage its cash flow. With a current P/E Ratio of 23.56 and an EV/EBITDA of 15.08, the company's valuation appears reasonable given its growth prospects. The 'Free Cash Flow Yield (%)' is 4.9%, indicating a decent return for investors.

Cybersecurity Breach and Operational Resilience

Regarding the cybersecurity breach, the company detected the attack on February 14 and engaged forensic incident response consultants. Fortunately, the breach caused minimal interruptions to operations, and the company expects no material impact from the incident. This demonstrates the company's operational resilience and ability to respond to disruptions.

Future Growth Prospects

The company expects continued robust growth in the patient services market and is well-positioned to capitalize on emerging trends. Analysts estimate next year's revenue growth at 5.7%, which is a reasonable expectation given the company's track record. With a strong ROIC of 13.9% and an ROE of 17.36%, the company is generating value for its shareholders. As R. Jeffrey Bailly concluded, the company is excited about the future, citing a long-term contract, positioning with key customers, and a smooth transition plan for the new CEO.

3. NewsRoom

Card image cap

UFP Industries Banks on Business Initiatives Amid Residential Weakness

Mar -11

Source: zacks.com

Card image cap

UFP Technologies to Present and Host 1X1 Investor Meetings at the Raymond James 47th Annual Institutional Investors Conference

Feb -27

Source: globenewswire.com

Card image cap

UFP Technologies, Inc. (UFPT) Q4 2025 Earnings Call Transcript

Feb -25

Source: seekingalpha.com

Card image cap

UFP Technologies (UFPT) Q4 Earnings Top Estimates

Feb -25

Source: zacks.com

Card image cap

UFP Technologies Announces Record 2025 Results

Feb -24

Source: globenewswire.com

Card image cap

UFP Industries Announces Fourth Quarter 2025 Results

Feb -23

Source: prnewswire.com

Card image cap

UFP Technologies to Report Fourth Quarter and Year-End 2025 Financial Results on February 24, 2026

Feb -19

Source: globenewswire.com

Card image cap

Public Sector Pension Investment Board Purchases 5,174 Shares of UFP Technologies, Inc. $UFPT

Feb -19

Source: defenseworld.net

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (14.01%)

6. Segments

Components, Subassemblies, Products and Packaging

Expected Growth: 14.0%

UFP Technologies, Inc.'s 14.0% growth is driven by increasing demand for medical devices and orthotics, growth in the aerospace and defense industries, and rising adoption of sustainable packaging solutions. The company's diversified product portfolio, including components, subassemblies, and custom packaging, positions it for continued growth.

Engineering Services

Expected Growth: 15.0%

UFP Technologies' Engineering Services segment growth of 15.0% is driven by increasing demand for custom packaging solutions, expansion into new markets, and strategic acquisitions. Additionally, the company's focus on innovation, quality, and customer service has led to strong customer retention and repeat business, contributing to the segment's growth.

Tooling and Machinery

Expected Growth: 13.0%

UFP Technologies' Tooling and Machinery segment growth of 13.0% is driven by increasing demand for custom fabrications, precision machining, and assembly services from the medical, aerospace, and defense industries. Additionally, strategic acquisitions and investments in new technologies have expanded the company's capabilities, further contributing to the segment's growth.

7. Detailed Products

Die-Cut Components

Custom die-cut components for medical devices, aerospace, and industrial applications

Molded Fiber Products

Custom molded fiber products for packaging, filtration, and acoustical applications

Foam Fabrication

Custom foam fabrication for medical devices, aerospace, and industrial applications

RF Ablation

Custom RF ablation components for medical devices

Catheter Components

Custom catheter components for medical devices

Bio-Based Materials

Custom bio-based materials for medical devices, packaging, and industrial applications

Cleanroom Manufacturing

Cleanroom manufacturing services for medical devices and aerospace applications

8. UFP Technologies, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for UFP Technologies, Inc. is medium because while there are some substitutes available, they are not highly attractive to customers.

Bargaining Power Of Customers

The bargaining power of customers for UFP Technologies, Inc. is low because customers have limited options and the company has a strong brand presence.

Bargaining Power Of Suppliers

The bargaining power of suppliers for UFP Technologies, Inc. is medium because while suppliers have some bargaining power, the company has a diversified supply chain.

Threat Of New Entrants

The threat of new entrants for UFP Technologies, Inc. is high because the industry has low barriers to entry and new entrants can easily enter the market.

Intensity Of Rivalry

The intensity of rivalry for UFP Technologies, Inc. is high because the industry is highly competitive and companies are constantly competing for market share.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 10.96%
Debt Cost 8.40%
Equity Weight 89.04%
Equity Cost 8.40%
WACC 8.40%
Leverage 12.31%

11. Quality Control: UFP Technologies, Inc. passed 8 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Biotricity

A-Score: 5.2/10

Value: 9.6

Growth: 5.6

Quality: 6.0

Yield: 0.0

Momentum: 10.0

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Tactile Systems Technology

A-Score: 4.9/10

Value: 3.1

Growth: 7.7

Quality: 7.1

Yield: 0.0

Momentum: 9.0

Volatility: 2.3

1-Year Total Return ->

View Full Report
Stock-Card
UFP Technologies

A-Score: 4.2/10

Value: 2.9

Growth: 9.1

Quality: 7.0

Yield: 0.0

Momentum: 2.5

Volatility: 4.0

1-Year Total Return ->

View Full Report
Stock-Card
Electromed

A-Score: 4.0/10

Value: 1.9

Growth: 8.8

Quality: 7.4

Yield: 0.0

Momentum: 2.0

Volatility: 3.7

1-Year Total Return ->

View Full Report
Stock-Card
Quipt Home Medical

A-Score: 3.8/10

Value: 8.2

Growth: 6.3

Quality: 3.8

Yield: 0.0

Momentum: 3.0

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
Sensus Healthcare

A-Score: 3.4/10

Value: 8.5

Growth: 6.6

Quality: 3.0

Yield: 0.0

Momentum: 1.0

Volatility: 1.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

209.59$

Current Price

209.59$

Potential

-0.00%

Expected Cash-Flows